2021 New Drug Approvals, By The Numbers

Last week, the FDA's Center for Drug Evaluation and Research released it 2021 report of New Drug Therapy Approvals. The approvals are notable for the potential to provide a positive impact on patient care. The following infographic shows some of the more notable statistics from this year's report.

According to the FDA, CDER approved 50 new drugs in 2021. The applications represented both new molecular entities under New Drug Applications or new therapeutic biologics under Biologics License Applications. In each case, the active ingredient or ingredients have never been approved in the U.S.

New drugs advance treatment options in heart, blood, kidney and endocrine disease; autoimmune, inflammatory and lung diseases; infectious disease; neurological and psychiatric disorders; cancer; and other orphan conditions.

98 percent of the approvals were granted within the Prescription Drug User Fee Act timeframes and nearly 90 percent were approved on the first cycle. The FDA credits this with earlier and more effective communication between manufacturers and the FDA. It is also likely due to the use of expedited approval pathways, including "fast track" and "breakthrough therapy" designation along with "priority review" and "accelerated approval."

Of note, CDER approved four new biosimilar products and the first two interchangeable biosimilar products, marking continued advancement in this market segment. Beyond novel drug approvals, the FDA approved 12 new formulations of drugs that had been previously approved. These include new formulations, new dosage forms and other non-novel drug approvals.

This report should be of interest to drug manufacturer, particularly given the level of coordination and collaborations needed to secure approval for new drugs. The FDA report shows that an effective, team-base collaboration with the FDA and other experts can lead to timely approval of safe and effective therapies for a wide range of medical conditions. We listen to their concerns and strive to see their perspectives. We know it is important to understand the needs of our key constituencies and take actions that will benefit as many Americans as possible.

For more information about this report, contact me at john@policypros.net

Comments

Innovative Models for Lowering Drug Spending

Recently, much has been written about the escalating costs of drug prices in the US. Increasing drug prices are present challenges to those who struggle with affordability and access to their medications. The Inflation Reduction Act brought changes to the way the Medicare program reimburses for prescription drugs. Last year, President Biden challenged the Center for Medicare and Medicaid Innovation (CMMI) to develop and test new payment models that can support value-based payments and promote high-quality healthcare. CMMI has recently proposed three models intended to improve affordability and access to drugs as well as measuring the feasibility of implementation. 1. The Medicare High-Value Drug List Model Under this model, Part D plans would be encouraged to offer a low, fixed co-payment across all cost-sharing phases of the Part D drug benefit for a standardized Medicare list of generic drugs that treat chronic conditions. Patients picking plans that participate in the Model wi

Bridging the Gap: The Long Road from FDA Approval to Medicare Coverage

A new study published in JAMA Health Forum reveals that the road to Medicare coverage for novel medical technologies is a long and winding one. Researchers found that only 44% of innovative devices and diagnostics approved by the FDA from 2016-2019 had even “nominal” Medicare coverage by 2022. This data highlights major hurdles in the system that delay patient access to beneficial emerging technologies. About the Research The study examined 281 novel products cleared through the FDA from 2016-2019 via the high-risk premarket approval, de novo, and breakthrough 510(k) pathways. These included things like groundbreaking diagnostic tests, implantable devices, and other innovative treatment technologies. The goal was to measure how long it took to establish national or regional Medicare coverage policies for these newly approved products. This is important because Medicare coverage is required before hospitals, physicians and patients can reliably access new technologies. Key Findings The

FDA Pilot Program for Certain In Vitro Diagnostic Tests

The U.S. Food and Drug Administration (FDA) has announced a pilot program designed to improve oncology patient care by establishing minimum performance standards for in vitro diagnostic tests (IVDTs) used with a limited number of oncology drug products. An IVDT is a device that provides critical information for the safe and effective use of a therapeutic product. The FDA typically requires a companion diagnostic to receive marketing authorization concurrently with the approval of the corresponding therapeutic product. However, in cases where no satisfactory alternative treatment exists for a serious or life-threatening condition, the FDA may approve a therapeutic product even without a companion IVDT. Currently, laboratory developed tests (LDTs) are being used in such cases, and the FDA exercises enforcement discretion regarding these tests. The pilot program aims to improve drug selection and patient care by establishing minimum performance characteristics for certain LDTs used in id

The Health Policy War Room

Search This Blog